The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
JK Mooi, P Wirapati, R Asher, CK Lee, P Savas, TJ Price, A Townsend, J Hardingham, D Buchanan, D Williams, S Tejpar, JM Mariadason, NC Tebbutt
Annals of Oncology | OXFORD UNIV PRESS | Published : 2018
Background: The consensus molecular subtypes (CMS) is a transcriptome-based classification of colorectal cancer (CRC) initially described in early-stage cohorts, but the associations of CMS with treatment outcomes in the metastatic setting are yet to be established. This study aimed to evaluate the prognostic impact of CMS classification and its predictive effects for bevacizumab benefit in metastatic CRC by correlative analysis of the AGITG MAX trial. Patients and methods: The MAX trial previously reported improved progression-free survival (PFS) for the addition of bevacizumab (B) to chemotherapy [capecitabine (C)±mitomycin (M)]. Archival primary tumours from 237 patients (50% of trial pop..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by NHMRC Senior Research Fellowship
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (1048088); Ludwig Cancer Research; the Operational Infrastructure Support Program, Victorian Government, Australia; NHMRC Senior Research Fellowship (1046092) to JMM; BEAT Cancer Council South Australia Grant to AT and PhD scholarship from Perpetual Philanthropic Grants (Reginald Marsden charitable trust) to JKM. Gene expression profiling was provided and carried out by Almac Diagnostics, Craigavon, UK.